FAPI PET Imaging - An Exploratory Study (FAPIPET)
FAPI PET Imaging - a Multicentric Exploratory Evaluation
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.
[18F]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well.
People who join this study will get one injection of the tracer into a vein, then have one PET/CT or PET/MR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed.
The study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Background and Rationale:
Fibroblast Activation Protein (FAP) is highly expressed in cancer-associated fibroblasts and in a range of fibrotic and inflammatory diseases. [18F]FAPI-74 is a novel PET radiotracer that binds selectively to FAP, enabling visualization of fibroblast activity. Early clinical studies have demonstrated promising tumour-to-background contrast, superior detectability compared with FDG in several tumours, and potential value in diseases where no adequate PET tracers exist. This multicentre study aims to systematically evaluate biodistribution, uptake patterns, and diagnostic usefulness of [18F]FAPI-74 across a broad spectrum of oncologic and non-oncologic indications.
Study Design:
This is an open-label, non-randomized, single-arm, exploratory diagnostic study conducted at five Swiss centres. Each participant undergoes a single administration of [18F]FAPI-74 followed by one PET/CT or PET/MR scan. No therapeutic interventions, follow-up visits, or repeat tracer administrations are planned. Standard-of-care imaging (e.g., FDG-PET/CT, PSMA-PET/CT, CT or MRI) already available for each participant is used as the reference for intra-individual comparison. The total radiation dose is approximately 7 mSv (≈3.5 mSv PET + ≈3.5 mSv low-dose CT), comparable to standard clinical PET/CT exposure.
Population:
Approximately 770 participants (age ≥18) will be recruited consecutively across 17 indication-specific subgroups: thyroid pathology; head and neck cancer (including cancer of unknown primary); neck node metastases from cancer of unknown primary; sinonasal tract tumor; sarcoidosis; thyroid cancer (suspected recurrence/persistence); breast cancer; hepatocellular carcinoma; gastric cancer; pancreatic cancer; prostate cancer (biochemical recurrence with negative PSMA-PET); urothelial carcinoma; multiple myeloma/plasmocytoma; mesothelioma; hepatic fibrosis; endometriosis; and lung fibrosis. Full eligibility criteria and per-indication enrollment targets are provided in the Eligibility Criteria module.
Investigational Medicinal Product:
[18F]FAPI-74 is a fluorine-18-labelled small-molecule inhibitor targeting FAP. Administered activity is approximately 250 MBq, with a permissible site-specific range of 200-300 MBq. Route of administration is intravenous slow bolus injection (5-15 seconds). The product is manufactured at the USZ Radiopharmacy under GMP conditions, using precursor material supplied by SOFIE Biosciences. Imaging is performed 45-60 minutes post-injection.
Procedures:
Screening includes eligibility assessment, informed consent, collection of demographic and clinical information, and review of historical imaging. Study Visit (Day 0) includes reconfirmation of eligibility, radiotracer injection, a 45-60 minute uptake phase, PET/CT or PET/MR acquisition, adverse event assessment, and discharge. This is a single-visit study; no follow-up visits are planned.
Outcomes:
Primary and secondary outcome definitions, including uptake classification, image quality rating, and comparison methodology against reference imaging, are provided in full in the Outcome Measures module.
Statistical Methods:
The study is descriptive and exploratory in nature. No hypothesis-driven power calculation was performed; sample size was determined based on prior experience with comparable diagnostic imaging studies, published literature, and feasibility considerations.
Quality Assurance:
Monitoring is performed by the Clinical Trials Center (CTC), University Hospital Zurich, in accordance with ICH-GCP and the Swiss Ordinance on Clinical Trials (ClinO). Study data are collected in REDCap® and pseudonymised; imaging data remain stored in institutional PACS systems under standard institutional access controls.
Funding and Insurance:
Each participating centre covers its own operational costs. Precursor material for [18F]FAPI-74 is supplied by SOFIE Biosciences under contractual agreement. Insurance coverage is provided through the Sponsor-Investigator's institutional policy (Baloise Versicherung AG), in accordance with ClinO Annex 2.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Martin Hüllner, Prof. Dr. med.
- 전화번호: 0041442552580
- 이메일: martin.huellner@usz.ch
연구 연락처 백업
- 이름: Patrick Perron, Masters Degree
- 전화번호: 0041442552827
- 이메일: patrick.perron@usz.ch
연구 장소
-
-
Canton of Aargau
-
Baden, Canton of Aargau, 스위스
- Kantonsspital Baden
-
연락하다:
- Irene Burger, Prof. Dr. med.
- 전화번호: 0041 56 486 38 80
- 이메일: irene.burger@ksb.ch
-
수석 연구원:
- Irene Burger, Prof. Dr. med.
-
-
Canton of Geneva
-
Geneva, Canton of Geneva, 스위스
- Hopitaux Universitaires de Geneve (HUG)
-
연락하다:
- Ismini Mainta, Dr. med.
- 전화번호: 0041223725201
- 이메일: isminicharis.mainta@hug.ch
-
수석 연구원:
- Ismini Mainta, Dr. med.
-
-
Canton of Lucerne
-
Lucerne, Canton of Lucerne, 스위스
- Luzerner Kantonsspital
-
연락하다:
- Klaus Strobel, Prof. Dr. med.
- 전화번호: 0041412054401
- 이메일: Klaus.strobel@luks.ch
-
수석 연구원:
- Klaus Strobel, Prof. Dr. med.
-
-
Canton of Vaud
-
Genolier, Canton of Vaud, 스위스
- Clinique de Genolier
-
연락하다:
- Antoine Leimgruber, Dr. med.
- 전화번호: 0041792642909
- 이메일: Aleimburger@swissmedical.net
-
수석 연구원:
- Antoine Leimgruber, Dr. med.
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, 스위스, 8091
- Department for Nuclear Medicine, University Hospital Zurich
-
연락하다:
- Patrick Perron
- 전화번호: 0041 44 255 28 27
- 이메일: patrick.perron@usz.ch
-
수석 연구원:
- Martin Hüllner, Prof. Dr. med.
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Written informed consent obtained and documented by the participant's signature.
- Age ≥18 years at the time of consent.
- Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol.
- Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT/MRI) to allow comparative evaluation.
Exclusion Criteria:
- Severe claustrophobia that would preclude PET imaging.
- Inability to remain still for the duration of the PET/MR examination.
- Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy.
- Previous hypersensitivity reactions to radiotracer administration
- Inability to understand the study information, for example due to language barriers.
- Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).
- Participants scheduled for PET/MR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: [18F]FAPI-74 PET Imaging
Participants receive a single intravenous injection of approximately 250 MBq [18F]FAPI-74 (fluorine-18 labelled FAP-targeted PET radiotracer), followed by one PET/CT or PET/MR scan performed 45-60 minutes post-injection.
For PET/CT acquisitions, a low-dose CT is performed for attenuation correction and anatomical localization.
No therapeutic intervention, randomization, or repeat tracer administration is involved.
Uptake and diagnostic image quality are assessed qualitatively by a nuclear medicine physician from the local study team.
Findings are compared with each participant's own previously acquired standard-of-care imaging (e.g., FDG-PET/CT, PSMA-PET/CT, CT, or MRI), which serves as the reference standard rather than a concurrent study arm.
Total participation time is approximately 2 hours on a single study day.
|
18F]FAPI-74 is a fluorine-18 labelled, quinoline-based small-molecule inhibitor targeting fibroblast activation protein (FAP), a transmembrane glycoprotein selectively expressed on cancer-associated fibroblasts and in fibrotic/inflammatory tissue.
Each participant receives a single intravenous slow-bolus injection (5-15 seconds) of approximately 250 MBq (permissible range 200-300 MBq), followed by a 45-60 minute uptake period and one PET/CT or PET/MR acquisition.
The product is manufactured under GMP at the USZ Radiopharmacy using precursor material supplied by SOFIE Biosciences.
Unlike clinically established PET tracers (e.g., FDG, PSMA-ligands), [18F]FAPI-74 is not yet authorized in Switzerland and is administered exclusively within this investigational protocol for diagnostic evaluation purposes only.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Diagnostic Interpretability and Uptake Classification of [18F]FAPI-74 PET Imaging
기간: At the time of [18F]FAPI-74 PET/CT or PET/MR image acquisition and interpretation, performed 45-60 minutes after tracer injection, on the single study visit day.
|
Qualitative assessment of [18F]FAPI-74 uptake by a local nuclear medicine physician, classified as FAPI-positive or FAPI-negative in target lesions or disease-specific regions.
Overall diagnostic image quality will additionally be rated using a 4-point scale: fully diagnostic, almost fully diagnostic, diagnostically limited, or non-diagnostic.
The primary analysis will report the proportion of participants with diagnostically interpretable [18F]FAPI-74 images, per indication and pooled across indications.
|
At the time of [18F]FAPI-74 PET/CT or PET/MR image acquisition and interpretation, performed 45-60 minutes after tracer injection, on the single study visit day.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lesion-Wise Comparison of [18F]FAPI-74 Uptake with Standard-of-Care Reference Imaging
기간: At the time of [18F]FAPI-74 image interpretation, compared against each participant's most recent standard-of-care reference imaging obtained as part of routine clinical care
|
Qualitative and semi-quantitative comparison of [18F]FAPI-74 uptake with each participant's available standard-of-care reference imaging (e.g., FDG-PET/CT, PSMA-PET/CT, or morphological imaging such as CT/MRI), performed on a lesion-wise basis.
Comparative ratings will classify [18F]FAPI-74 findings as providing more, comparable, or less diagnostic information relative to the reference imaging.
Where available, histopathology or composite clinical/imaging follow-up will serve as the reference standard for calculating sensitivity, specificity, and positive predictive value per indication.
|
At the time of [18F]FAPI-74 image interpretation, compared against each participant's most recent standard-of-care reference imaging obtained as part of routine clinical care
|
|
Change in Diagnostic Confidence and Clinical Management Following [18F]FAPI-74 Imaging
기간: Diagnostic confidence and management recommendations assessed immediately before and after review of [18F]FAPI-74 imaging, on the single study visit day.
|
Change in diagnostic confidence and clinical management recommendations, determined by comparing physician assessments performed before versus after review of [18F]FAPI-74 imaging.
Diagnostic confidence will be rated on a defined scale; management change will be recorded as a binary indicator (yes/no), with the type of change categorized (e.g., additional biopsy recommended, therapy switch, change in staging).
Clinical impact of [18F]FAPI-74 findings will additionally be classified as major impact (change in diagnosis or management), minor impact (additional findings not altering management), or no impact.
|
Diagnostic confidence and management recommendations assessed immediately before and after review of [18F]FAPI-74 imaging, on the single study visit day.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Martin Hüllner, Prof. Dr. med., Department for Nuclear Medicine, University Hospital Zurich
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 생식기 질환
- 내분비계 질환
- 혈관 질환
- 심혈관 질환
- 병리학적 과정
- 생식기 신생물, 남성
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 생식기 질환, 남성
- 전립선 질환
- 남성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 면역계 질환
- 호흡기 질환
- 조직학적 유형에 따른 신생물
- 위장관 신생물
- 소화계 신생물
- 소화기계 질환
- 위장병
- 위장병
- 생식기 질환, 여성
- 폐 질환
- 과민증
- 혈액 질환
- 내분비샘 신생물
- 간 질환
- 신생물, 선상 및 상피
- 선암종
- 간 신생물
- 선종
- 신생물, 중피
- 피부병
- 유방 질환
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 암종
- 폐 질환, 간질
- 신생물, 형질세포
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 출혈성 장애
- 갑상선 질환
- 섬유증
- 과민증, 지연
- 병리학적 상태, 징후 및 증상
- 피부 및 결합 조직 질환
- 헴 및 림프병
- 전립선 신생물
- 위 신생물
- 암종, 간세포
- 중피종
- 유방 신생물
- 질병
- 폐 섬유증
- 다발성 골수종
- 두경부 신생물
- 간경화
- 암종, 과도기 세포
- 형질세포종
- 자궁내막증
- 유육종증
- 갑상선 신생물
- 췌장암, 성인
기타 연구 ID 번호
기타 연구 ID 번호
- BASEC 2026-OO454 (기타 식별자: swissethics)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .